Prospective Long-term Outcomes of a Cohort of Ugandan Children with Laboratory Monitoring During Antiretroviral Therapy

Pediatric Infectious Disease Journal

Volumn 31, Issue 8, 2012, Pages e117-e125

  Kekitiinwa, Adeodata ^a   Asiimwe, Alice R ^a   Kasirye, Philip ^a   Korutaro, Violet ^a   Kitaka, Sabrina ^a   Maganda, Albert ^a   Madalon, Michael ^a   Graziano, Frank M ^a  

^a MULAGO HOSPITAL   (Uganda)

Author keywords

Antiretroviral therapy; Long term analysis; Resistance mutations; Ugandan children; Viral load

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ANEMIA; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; DIARRHEA; DIZZINESS; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; INFANT; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; NEOPLASM; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY TRACT INFECTION; SCHOOL CHILD; SIDE EFFECT; STUNTING; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; WEIGHT REDUCTION;

ADOLESCENT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; MALE; MUTATION; PROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT OUTCOME; UGANDA; VIRAL LOAD;

EID: 84863988154     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31825cb9d6     Document Type: Article

References (35)

1. WHO/UNAIDS. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. WHO/UNAIDS Progress Report, September. 2009:p.4
2. Gazzard B. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). HIV Med. 2005;6(suppl 2):1-61
3. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006;296:827-843
4. Eley B, Davies MA, Apolles P, et al. Antiretroviral treatment for children. S Afr Med J. 2006;96(9 pt 2):988-993
5. Jooste JP, Van Zyl AJ, Baker A, et al. Antiretroviral treatment in the Northern Cape. S Afr Med J. 2005;95:812
6. Reddi A, Leeper SC, Grobler AC, et al. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatr. 2007;7:13
7. Sutcliffe CG, van Dijk JH, Bolton C, et al. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis. 2008;8:477-489
8. The Kids-ART-LINC Collaboration low risk of death, but substantial program attrition, in pediatric treatment cohorts in sub-Saharan Africa. J Aquir Immune Defic Syndr. 2008;15:523-531
9. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA. 2007;298:1888-1899
10. Nyandiko WM, Ayaya S, Nabakwe E, et al. Outcomes of HIV-infected orphaned and non-orphaned children on antiretroviral therapy in western Kenya. J Acquir Immune Defic Syndr. 2006;43:418-425
11. Musoke PM, Mudiope P, Barlow-Mosha LN, et al. Growth, immune and viral responses in HIV infected African children receiving highly active antiretroviral therapy: a prospective cohort study. BMC Pediatr. 2010;10:56
12. Ghaffari G, Passalacqua DJ, Caicedo JL, et al. Two-year clinical and immune outcomes in human immunodeficiency virus-infected children who reconstitute CD4 T cells without control of viral replication after combination antiretroviral therapy. Pediatrics. 2004;114:e604-e611
13. Davies MA, Keiser O, Technau K, et al. Outcomes of the South African National Antiretroviral Treatment Programme for children: the IeDEA Southern Africa collaboration. S Afr Med J. 2009;99:730-737
14. Paintsil E. Monitoring antiretroviral therapy in HIV-infected children in resource-limited countries: a tale of two epidemics. AIDS Res Treat. 2011;2011:280901
15. Rouet F, Fassinou P, Inwoley A, et al. Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens. AIDS. 2006;20:2315-2319
16. Ruel TD, Kamya MR, Li P, et al. Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children. J Acquir Immune Defic Syndr. 2011;56:44-50
17. Davies MA, Moultrie H, Eley B, et al. Virologic failure and second-line antiretroviral therapy in children in South Africa-the IeDEA Southern Africa collaboration. J Acquir Immune Defic Syndr. 2011;56:270-278
18. Barth RE, Tempelman HA, Smelt E, et al. Long-term outcome of children receiving antiretroviral treatment in rural South Africa: substantial virologic failure on first-line treatment. Pediatr Infect Dis J. 2011;30:52-56
19. Antiretroviral therapy of HIV infection in infants and children: towards universal access. Recommendations for a public health approach: 2010 revision. 2010 Geneva, Switzerland World Health Organization September. Avaialable at: http://www.who.int/hiv/pub/guidelines/art/index.html. Accessed November 1, 2011.
20. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE. 2009;4:e4724
21. Stanford University HIV drug resistance database. Avaialable at: http://hivdb.stanford.edu. Accessed November 1, 2011.
22. DART Trial Team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet. 2010;375:123-131
23. Bakanda C, Birungi J, Mwesigwa R, et al. Survival of HIV-infected adolescents on antiretroviral therapy in Uganda: findings from a nationally representative cohort in Uganda. PLoS ONE. 2011;6:e19261
24. Barlow-Mosha L, Midiope P, Massavon W, et al. Virologic response among antiretroviral experienced Ugandan children on NNRTI based first-line therapy enrolled in antiretroviral treatment (ART) using clinical and immunologic criteria to assess response to therapy. 18th Conference on Retroviruses and Opportunistic Infections. February 27-March 2 Boston, MA. Abstract #682.
25. Deeks SG, Barbour JD, Grant RM, et al. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS. 2002;16:201-207
26. van Rossum AM, Fraaij PL, de Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis. 2002;2:93-102
27. Towler WI, Barlow-Mosha L, Church JD, et al. Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda. AIDS Res Hum Retroviruses. 2010;26:563-568
28. Cozzi-Lepri A, Phillips AN, Martinez-Picado J, et al. Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings. J Infect Dis. 2009;200:687-697
29. Lai MT, Lu M, Felock PJ, et al. Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2010;54:4812-4824
30. Martinez-Cajas JL, Pai NP, Klein MB, et al. Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008). J Int AIDS Soc. 2009;12:11
31. Wainberg MA, Zaharatos GJ, Brenner BG. Mechanisms of disease: Development of antiretroviral drug resistance. N Engl J Med. 2011;365:637-646
32. Castelnuovo B, John L, Lutwama F, et al. Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: good virological response but high rate of toxicity. J Int Assoc Physicians AIDS Care (Chic). 2009;8:52-59
33. Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for ­children with peripartum nevirapine exposure. N Engl J Med. 2010;363:1510-1520
34. Ren J, Bird LE, Chamberlain PP, et al. Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc Natl Acad Sci U S A. 2002;99:14410-14415
35. Peytavin G, Mynard JL, Vray M, et al. Impact of non-nucleoside reverse transcriptase inhibitors (NNRTIs) plasma concentrations on virological response to antiretroviral therapy in HIV-1 infected NNRTIs naive-patients (pts) enrolled in ANRS 088 trial. 9th European AIDS Conference; 2003;October 25-29 Warsaw, Poland. Abstract F2/1.